よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (35 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
VSD incidence rates of verified myocarditis/pericarditis in the 0–7 days after
Pfizer-BioNTech vaccination in people ages 5–39 years, dose 2 and 1st booster*
1st booster dose
Pfizer-BioNTech
Dose 2 primary series
Pfizer-BioNTech
Cases
Dose 2
admin
Incidence rate/
million doses (95% CI)
Cases
1st boosters
admin
Incidence rate/
million doses (95% CI)
5-11 years
Males
Females
12–15 years
Males
Females
3
0
207,958
202,596
14.4 (3.0 – 42.2)
0.0 (0.0 – 14.8)
0
0
50,415
49,261
0.0 (0.0 – 59.4)
0.0 (0.0 – 60.8)
31
5
205,955
204,074
150.5 (102.3 – 213.6)
24.5 (8.0 – 57.2)
5
0
81,613
84,114
61.3 (19.9 – 143.0)
0.0 (0.0 – 35.6)
16–17 years
Males
Females
14
1
102,091
107,173
137.1 (75.0 – 230.1)
9.3 (0.2 – 52.0)
9
2
47,874
55,004
188.0 (86.0 – 356.9)
36.4 (4.4 – 131.3)
18–29 years
Males
Females
27
2
331,889
400,321
81.4 (53.6 – 118.4)
5.0 (0.6 – 18.0)
7
1
166,973
240,226
41.9 (16.9 – 86.4)
4.2 (0.1 – 23.2)
30–39 years
Males
Females
5
3
341,527
410,713
14.6 (4.8 – 34.2)
7.3 (1.5 – 21.3)
3
1
197,554
268,412
15.2 (3.1 – 44.4)
3.7 (0.1 – 20.8)
*Primary series surveillance for people ages ≥18 years ended May 21, 2022, all other data through August 20, 2022.
35
Pfizer-BioNTech vaccination in people ages 5–39 years, dose 2 and 1st booster*
1st booster dose
Pfizer-BioNTech
Dose 2 primary series
Pfizer-BioNTech
Cases
Dose 2
admin
Incidence rate/
million doses (95% CI)
Cases
1st boosters
admin
Incidence rate/
million doses (95% CI)
5-11 years
Males
Females
12–15 years
Males
Females
3
0
207,958
202,596
14.4 (3.0 – 42.2)
0.0 (0.0 – 14.8)
0
0
50,415
49,261
0.0 (0.0 – 59.4)
0.0 (0.0 – 60.8)
31
5
205,955
204,074
150.5 (102.3 – 213.6)
24.5 (8.0 – 57.2)
5
0
81,613
84,114
61.3 (19.9 – 143.0)
0.0 (0.0 – 35.6)
16–17 years
Males
Females
14
1
102,091
107,173
137.1 (75.0 – 230.1)
9.3 (0.2 – 52.0)
9
2
47,874
55,004
188.0 (86.0 – 356.9)
36.4 (4.4 – 131.3)
18–29 years
Males
Females
27
2
331,889
400,321
81.4 (53.6 – 118.4)
5.0 (0.6 – 18.0)
7
1
166,973
240,226
41.9 (16.9 – 86.4)
4.2 (0.1 – 23.2)
30–39 years
Males
Females
5
3
341,527
410,713
14.6 (4.8 – 34.2)
7.3 (1.5 – 21.3)
3
1
197,554
268,412
15.2 (3.1 – 44.4)
3.7 (0.1 – 20.8)
*Primary series surveillance for people ages ≥18 years ended May 21, 2022, all other data through August 20, 2022.
35